First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

Rhythm Pharmaceuticals’ setmelanotide receives US FDA approval to treat patients living with acquired hypothalamic obesity: Boston Saturday, March 21, 2026, 18:00 Hrs [IST] Rhyt ...

FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

Rhythm Pharmaceuticals received Food and Drug Administration approval for an expanded indication for setmelanotide, its treatment for acquired hypothalamic obesity. Acquired hypothalamic obesity is a ...

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s RYTM Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). The ...

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer The Oncology Grand Rounds series is designed to place original reports ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) shares rose 11% Friday morning following FDA approval of IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity. The approval marks the first and ...

Hypothalamic obesity is a complex condition that doesn’t always respond to traditional weight loss methods. Medications, hormonal therapy, and surgery may be necessary to see results. Hypothalamic ...

This is due to epigenetic components: microRNA, histone and DNA methylation, gene mutations that alter the expression and production of the neurotrophic factor BDNF, which interacts with the receptors ...